Patrick Chaltin

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Skeletal Muscle

Cell Proliferation

Top Venues

Cellular and molecular life sciences : CMLS

The Journal of experimental medicine

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Hanne Hillen, Aurelie Candi, Bart Vanderhoydonck, Weronika Kowalczyk, Leticia Sansores-García, Elena C Kesikiadou, Leen Van Huffel, Lore Spiessens, Marnik Nijs, Erik Soons, Wanda Haeck, Hugo Klaassen, Wim Smets, Stéphane A Spieser, Arnaud Marchand, Patrick Chaltin, Fabrice Ciesielski, Francois Debaene, Lei Chen, Adeela Kamal, Stephen L Gwaltney, Matthias Versele, Georg A Halder
A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models. Molecular cancer therapeutics (2023)
Tom Van Loy, Steven De Jonghe, Karolien Castermans, Wouter Dheedene, Reinout Stoop, Lars Verschuren, Matthias Versele, Patrick Chaltin, Aernout Luttun, Dominique Schols
Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model. Cellular and molecular life sciences : CMLS 79 (6) (2022)
Tim Pieters, Sara T'Sas, Stijn Vanhee, André Almeida, Yasmine Driege, Juliette Roels, Wouter Van Loocke, Willem Daneels, Mathijs Baens, Arnaud Marchand, Maaike Van Trimpont, Filip Matthijssens, Julie Morscio, Kelly Lemeire, Béatrice Lintermans, Lindy Reunes, Patrick Chaltin, Fritz Offner, Jo Van Dorpe, Tino Hochepied, Geert Berx, Rudi Beyaert, Jens Staal, Pieter Van Vlierberghe, Steven Goossens
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice. The Journal of experimental medicine 218 (10) (2021)